ACM
PCRX icon

Aster Capital Management’s Pacira BioSciences PCRX Stock Holding History

Aster Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.85K Buy
+316
New +$7.02K ﹤0.01% 647
2025
Q3 		– Sell
-212
Closed -$5.07K – 1272
2025
Q2 		$5.07K Buy
+212
New +$5.34K ﹤0.01% 859

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aster Capital Management's PCRX Position: Q1 2026 in Review

Aster Capital Management opened a new position in Pacira BioSciences (PCRX) in Q1 2026: 316 shares worth $7.85K. The stake represents ﹤0.01% of the portfolio and ranks #647 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in PCRX as recently as Q2 2025.

Aster Capital Management first reported a position in PCRX in Q2 2025 and has held it in 2 quarters since. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Aster Capital Management held 316 shares of Pacira BioSciences worth $7.85K as of Q1 2026.
  • Pacira BioSciences was a new Aster Capital Management position in Q1 2026.
  • Pacira BioSciences made up ﹤0.01% of Aster Capital Management's portfolio in Q1 2026, its #647 holding.
  • Aster Capital Management first reported a position in Pacira BioSciences in Q2 2025 and has held it in 2 quarters since.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.